Dimension Therapeutics is developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. Dimension’s lead programs address significant medical needs for new therapies and include a wholly owned program in hemophilia B, which entered clinical testing in January 2016, additional programs in OTC deficiency, GSDIa, citrullinemia type 1, Wilson disease, and a collaboration with Bayer HealthCare in hemophilia A. The Company also is seeking to expand its pipeline with additional rare disease programs.
Dimension’s leadership team, thought leader advisors, and collaborative partners bring to the company broad and deep expertise in global research, clinical development, and market access of gene therapies and orphan products across the spectrum of neonate, pediatric, and adult patient populations. The Company has built a unique and robust in-house engine of process development for the manufacture of our AAV-based therapeutics. To augment our internal capabilities, we have established collaborations and partnerships with leading specialized contract manufacturing organizations (CMOs) to enable the advancement of our portfolio in to the clinic